PT-141 (Bremelanotide) and Finasteride Interaction: What Women Need to Know

What Are These Two Drugs and Why Would a Woman Take Both?

Bremelanotide and finasteride serve very different primary purposes, yet some women end up prescribed or seeking both at the same time. Understanding what each drug does, separately, is the starting point for evaluating any interaction.

Bremelanotide, sold as Vyleesi, is an FDA-approved melanocortin receptor agonist indicated specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It works by activating MC1R and MC4R receptors in the central nervous system, increasing dopaminergic and noradrenergic tone in pathways that regulate sexual motivation. You inject it subcutaneously about 45 minutes before anticipated sexual activity, and the approved dose is 1.75 mg; it is not intended as a daily medication.

Finasteride is a 5-alpha reductase (5-AR) inhibitor approved by the FDA for benign prostatic hyperplasia and male-pattern hair loss. In women, it is used entirely off-label, most often for female pattern hair loss (FPHL) and occasionally for androgen-excess conditions such as PCOS-associated hirsutism. A typical off-label dose in women ranges from 1 mg to 5 mg orally per day, though evidence supporting these doses in women is largely extrapolated from male trials.

A woman might be prescribed or seek both drugs if she has FPHL or PCOS-related androgen excess (finasteride) alongside HSDD (bremelanotide). The combination is not rare in a telehealth setting.

How Each Drug Works at the Molecular Level

Bremelanotide: After subcutaneous injection, bremelanotide binds melanocortin receptors (primarily MC4R) in the hypothalamus and limbic system. It does not meaningfully inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, and it is not a P-glycoprotein substrate or inhibitor at clinically relevant concentrations, according to the FDA prescribing information. Its half-life is approximately 2.7 hours.

Finasteride: Finasteride competitively inhibits type II and type III 5-alpha reductase, blocking the conversion of testosterone to the more potent dihydrotestosterone (DHT). It is metabolized primarily by CYP3A4 in the liver and has a half-life of 5 to 6 hours in younger adults, extending to 8 hours in women over 70. It is not a meaningful inhibitor or inducer of CYP enzymes at therapeutic doses.

The Pharmacokinetic Picture: Is There a True Drug-Drug Interaction?

The short answer is no recognized pharmacokinetic DDI exists. Neither drug meaningfully alters the metabolism, absorption, distribution, or elimination of the other.

Bremelanotide's metabolic profile is essentially hepatic peptide cleavage and renal excretion of metabolites. It does not rely on CYP3A4. Finasteride relies on CYP3A4 but does not inhibit it at standard doses. The FDA label for bremelanotide lists no interactions with 5-AR inhibitors, and no published case reports or DDI studies address this specific pairing.

Major DDI databases (Lexicomp, Micromedex, DrugBank) do not flag a clinically significant interaction between bremelanotide and finasteride. From a classical pharmacokinetics standpoint, combining them does not alter drug levels of either agent.

Where the Biology Gets More Complicated

The absence of a pharmacokinetic interaction does not mean the combination is without clinical nuance. Both drugs intersect with the androgen axis, and that intersection matters differently depending on your life stage and hormonal status.

Bremelanotide's mechanism sits upstream of androgens, at the level of central nervous system desire circuitry. But sexual desire in women is not purely CNS. Testosterone and its androgen metabolites contribute to libido through both central and peripheral pathways, and finasteride, by suppressing DHT, may modestly reduce the androgen-mediated component of sexual motivation. This pharmacodynamic concern, rather than a PK interaction, is the relevant clinical question.

Finasteride, DHT, and Female Sexual Function

The data here are limited and women are significantly underrepresented in the relevant trials. In men, finasteride at 5 mg daily is associated with decreased libido in approximately 1.8% of patients in clinical trials, though post-market reports suggest this figure may underestimate real-world frequency. In women, this side-effect profile has not been studied in adequately powered trials.

A clinically useful way to think about this pairing is the "central plus peripheral desire model for women": bremelanotide acts centrally (hypothalamic MC4R activation raises desire drive), while finasteride acts peripherally (reducing DHT may lower the androgen substrate that supports the peripheral component of that same desire response). Whether one cancels the other in a meaningful way for any individual woman depends on her baseline androgen levels, her hormonal life stage, and whether DHT suppression is already affecting her subjectively. No trial has tested this combination in women. That evidence gap is real and should inform your conversation with your prescriber.

Sex-Specific Physiology: Why Your Hormonal Life Stage Changes Everything

Reproductive Years (Premenopausal)

Bremelanotide is approved only for premenopausal women with HSDD. During reproductive years, endogenous estrogen and progesterone fluctuate across the menstrual cycle and influence both libido and androgen sensitivity. Testosterone peaks around mid-cycle in many women, and this peak contributes to the natural surge in sexual desire that some women notice around ovulation. Finasteride blunts DHT at all cycle phases. Whether this suppression is clinically meaningful for sexual function in women with normal baseline androgens is unknown, but in women who already have low-normal testosterone (common in those using combined hormonal contraceptives), adding finasteride's DHT suppression may compound the effect.

If you are in your reproductive years taking both drugs, tracking your subjective desire across your cycle, before and after starting finasteride, gives you and your clinician useful real-world data.

PCOS and Androgen Excess

Women with PCOS who are prescribed finasteride for hirsutism or hair loss represent a subgroup with chronically elevated androgens. In this group, the pharmacodynamic concern about finasteride reducing the androgen substrate for desire is less pressing, because baseline DHT is elevated. PCOS affects approximately 6% to 12% of US women of reproductive age, and HSDD is more prevalent in women with PCOS than in the general population, so the clinical scenario of someone seeking both drugs is plausible. Bremelanotide in this subgroup has not been specifically studied.

Perimenopause

Bremelanotide is not FDA-approved for perimenopausal or postmenopausal women with HSDD. The key trials (RECONNECT studies) enrolled premenopausal women exclusively. If you are in perimenopause, your estrogen is declining and your androgens are also falling, which may make the DHT-suppressive effect of finasteride more clinically relevant to sexual function than it would be in a 28-year-old with strong androgen production. Prescribing bremelanotide off-label in perimenopause is a decision that requires explicit discussion with your clinician, and adding finasteride to that picture adds another layer of uncertainty.

Postmenopause

Postmenopausal women are outside the labeled indication for bremelanotide entirely. Androgen levels are substantially lower after menopause. The theoretical concern about finasteride further suppressing DHT and impairing desire is greatest in this group, but both drugs are being used off-label if prescribed in a postmenopausal context.

Pregnancy and Lactation: A Non-Negotiable Section

This section is mandatory reading if there is any chance you could become pregnant.

Finasteride: Pregnancy Category X. Stop Here and Read This.

Finasteride is FDA Pregnancy Category X. It is contraindicated in pregnancy. The mechanism of harm is direct: by inhibiting 5-AR, finasteride blocks the DHT required for normal male fetal genitalia development. A pregnant woman exposed to finasteride, or even to crushed finasteride tablets through skin contact, risks feminization of a male fetus. This is not a theoretical risk; it is the basis for the pregnancy contraindication.

If you are prescribed finasteride off-label as a woman of reproductive potential, you must use reliable contraception throughout treatment. The FDA label for Propecia (finasteride 1 mg) states that women who are or may become pregnant should not handle crushed or broken tablets. Your prescriber should confirm your contraceptive plan before your first prescription.

ACOG Committee Opinion supports counseling women of reproductive age about teratogenic medications and ensuring contraceptive access before prescribing. This is not an optional conversation.

Bremelanotide in Pregnancy

Bremelanotide is also contraindicated in pregnancy. Animal studies showed decreased pup survival and adverse fetal effects at doses approximating human exposure. No adequate human data exist. The FDA label states: discontinue bremelanotide if pregnancy occurs. A urine pregnancy test before initiation is part of standard prescribing practice.

Lactation

Neither bremelanotide nor finasteride has adequate human lactation data. Bremelanotide's FDA label states that animal data showed excretion into breast milk and that potential risks to the nursing infant cannot be excluded. Finasteride is not labeled for lactating women, and data on transfer into human breast milk are absent. Avoid both drugs while breastfeeding unless a clinician has reviewed the benefit-risk balance explicitly with you.

Contraception Requirements When Taking Both

If you are taking finasteride for any indication and you are of reproductive age, you need contraception. Adding bremelanotide, which is itself contraindicated in pregnancy, means two independent reasons to confirm your contraceptive method is reliable. IUDs (hormonal or copper) and implants are highly effective options. Combined oral contraceptives are effective but may themselves lower free testosterone, which could interact with the androgen pathway in ways that compound finasteride's effect on libido.

Who This Is Right For and Who Should Avoid the Combination

Women for Whom This Combination May Be Reasonable

• Premenopausal women with confirmed HSDD (bremelanotide's approved indication) who are also being treated for FPHL or PCOS-associated androgen excess with finasteride, on reliable contraception, with monitored blood pressure before each bremelanotide dose.
• Women with PCOS and elevated baseline androgens, where finasteride's DHT suppression is less likely to cause clinically meaningful additional reduction in libido.

Women Who Should Avoid or Reconsider

• Anyone who is pregnant or planning pregnancy in the near term. Both drugs are contraindicated.
• Women using no contraception while of reproductive age, given finasteride's Category X status.
• Women with a history of significant blood pressure variability. Bremelanotide causes a transient increase in blood pressure of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking at 4 hours post-dose and resolving within 12 hours. This risk is independent of finasteride but requires pre-dose blood pressure confirmation.
• Postmenopausal women who would be using both drugs off-label without clear evidence to support the combination.

Monitoring and Dose Considerations

Bremelanotide Monitoring

• Check blood pressure before each use. Do not use bremelanotide if blood pressure is elevated (systolic above 130 or diastolic above 80 mmHg) without clinician guidance.
• Limit use to no more than one dose per 24 hours. The RECONNECT trials capped use at approximately once monthly during the 24-week study period to assess efficacy; real-world use frequency is determined by the prescriber.
• Monitor for injection-site reactions and nausea, which occurred in 40% and 40% of women in the RECONNECT studies, respectively.
• Focal hyperpigmentation (darkening of the face, gums, or breasts) occurs in 1% of users with chronic use. Bremelanotide's MC1R activity drives melanogenesis. This risk increases with higher cumulative exposure.

Finasteride Monitoring in Women

• Liver function tests at baseline and periodically, as finasteride undergoes hepatic metabolism.
• Serum androgens (total testosterone, free testosterone, DHEAS) at baseline and every 6 to 12 months if treating FPHL or PCOS.
• Pregnancy test before initiation and ongoing contraceptive review.
• Hair count or standardized photography at 6 and 12 months to assess FPHL response, because clinical response in women typically requires 12 months of therapy.

Dose Adjustment for the Combination

No dose adjustment to either drug is required based on the combination alone. There is no PK interaction driving dose changes. However, if a woman reports worsening HSDD symptoms after starting finasteride, that is a clinical signal to reassess whether the androgen pathway suppression is contributing, and whether bremelanotide's dose timing or frequency needs to be discussed with the prescriber.

Counseling Points for Your Appointment

When you speak with your clinician about taking these two drugs together, here are specific questions worth asking:

• What is your baseline free testosterone and DHT? If already low-normal, finasteride's additional suppression may matter more.
• Are you on hormonal contraception that itself suppresses androgens (combined OCP)? This creates a three-way androgen suppression scenario worth mapping out.
• What is your blood pressure today, and do you have a home cuff to check it before each bremelanotide dose?
• Is the finasteride being used for a condition where another agent (spironolactone, for example) might be equally effective with a different side-effect profile?

A 2019 systematic review in the Journal of the American Academy of Dermatology concluded that finasteride 1 mg to 5 mg daily produces measurable improvement in female pattern hair loss at 12 months, with sexual side effects reported in a small but non-zero percentage of women, though the studies were underpowered to quantify this reliably. That evidence gap applies directly to the question of combining finasteride with a pro-desire drug.

"Women have been systematically excluded from drug trials in ways that leave clinicians without the sex-specific data they need to make confident prescribing decisions," according to the FDA's Action Plan for Women's Health. This gap is particularly acute for off-label finasteride use in women.

"The RECONNECT trials established bremelanotide's efficacy in premenopausal women, but the enrolled population was carefully selected and excluded women with cardiovascular risk factors, leaving real-world applicability questions open," as noted in the primary RECONNECT publication in Obstetrics and Gynecology.

The Evidence Gap: What We Simply Do Not Know Yet

Women are underrepresented in pharmacological research. This statement is not a formality. For this specific combination:

• No randomized controlled trial has tested bremelanotide and finasteride together in women.
• No pharmacokinetic interaction study exists for this pairing.
• Finasteride's effect on female sexual function has not been studied in adequately powered trials at any dose.
• Bremelanotide has not been tested in women with PCOS, perimenopausal women, or postmenopausal women.
• The interaction between hormonal contraceptive androgen suppression, finasteride DHT suppression, and bremelanotide's CNS desire activation has not been modeled or studied.

What is directly studied: bremelanotide's efficacy vs. Placebo in premenopausal HSDD (RECONNECT studies), and finasteride's efficacy for FPHL in small trials. Everything about combining them is extrapolated from mechanism and clinical reasoning.